J. Russo

A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

L. Staudt, R. Gascoyne, G. Salles, 2017, Clinical Cancer Research.

ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma

R. Gascoyne, D. Scott, M. Czuczman, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R2‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B‐cell lymphoma

R. Gascoyne, D. Scott, M. Czuczman, 2019, Hematological Oncology.

Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma

R. Gascoyne, D. Scott, T. Witzig, 2020, Haematologica.

Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies

R. Gascoyne, D. Scott, M. Czuczman, 2019, Blood.

Results of real-time cell-of-origin subtype identification by gene expression profiling in patients with ABC-type diffuse large B-cell lymphoma in the phase III trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP (ROBUST).

R. Gascoyne, D. Scott, T. Witzig, 2018 .